| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| OMIDENEPAG (is an active metabolite)
| OMIDENEPAG | SENSORY | - | PROSTAGLANDIN E2 (EP2) RECEPTOR | Prostaglandin E2 receptor EP2 subtype UNIPROT P43116 more at DrugCentral | EMA | ||||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| OMIDENEPAG ISOPROPYL DISCONTINUED (has an active metabolite)
| OMIDENEPAG ISOPROPYL | SENSORY | OPHTHALMIC | SOLUBILITY PRACTICALLY INSOLUBLE IN WATER | PROSTAGLANDIN E2 (EP2) RECEPTOR | Prostaglandin E2 receptor EP2 subtype UNIPROT P43116 PTGER2 more at DrugCentral | EMA | |||
